↓ Skip to main content

Cochrane Database of Systematic Reviews

Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension

Overview of attention for article published in Cochrane database of systematic reviews, March 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

news
1 news outlet
blogs
1 blog
twitter
21 tweeters
facebook
4 Facebook pages
wikipedia
1 Wikipedia page
video
5 video uploaders

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
139 Mendeley
Title
Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension
Published in
Cochrane database of systematic reviews, March 2016
DOI 10.1002/14651858.cd007435.pub3
Pubmed ID
Authors

Meghan J Ho, Edmond CK Li, James M Wright

Abstract

Blood pressure is a commonly measured risk factor for non-fatal and fatal cardiovascular adverse events such as heart attacks and strokes. Clinical trials have suggested that coenzyme Q10, a non-prescription nutritional supplement, can effectively lower blood pressure (BP). When this review was completed and published in October 2009, it concluded that "due to the possible unreliability of the 3 included studies, it is uncertain whether or not coenzyme Q10 reduces blood pressure in the long-term management of primary hypertension." To determine the blood pressure lowering effect of coenzyme Q10 in primary hypertension. We searched the Hypertension Group Specialised Register (1946 to November 2015), The Cochrane Central Register of Controlled Trials (The Cochrane Library 2015, Issue 10), MEDLINE (1946 to November 2015), MEDLINE In-Process (accessed 10 November 2015), EMBASE (1974 to November 2015), Web of Science (1899 to November 2015), CINAHL (1970 to November 2015), and ClinicalTrials.gov (accessed 10 November 2015). We also searched reference lists of articles for relevant clinical trials in any language. Double blind, randomized, placebo-controlled parallel or cross-over trials evaluating the blood pressure (BP) lowering efficacy of coenzyme Q10 for a duration of at least three weeks, in patients with primary hypertension. The primary author determined trial inclusion, extracted the data and assessed the risk of bias. The second author independently verified trial inclusion and data extraction. In this update of the review, one new randomized, controlled cross-over trial with a total of 30 participants was added, and one trial included in the initial review was excluded. Only two of the three included trials were pooled in the meta-analysis, as one trial was judged to have an unacceptably high risk of bias. In the meta-analysis of two RCTs (50 participants), coenzyme Q10 did not significantly change systolic BP: -3.68 mm Hg (95% confidence interval (CI) -8.86 to 1.49), or diastolic BP: -2.03 mm Hg (95% CI -4.86 to 0.81] ), based on clinic data. This review provides moderate-quality evidence that coenzyme Q10 does not have a clinically significant effect on blood pressure. In one of three trials reporting adverse effects, coenzyme Q10 was well tolerated. Due to the small number of individuals and studies available for analysis, more well-conducted trials are needed.

Twitter Demographics

The data shown below were collected from the profiles of 21 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 139 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 139 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 26 19%
Student > Master 26 19%
Researcher 17 12%
Student > Postgraduate 10 7%
Other 10 7%
Other 22 16%
Unknown 28 20%
Readers by discipline Count As %
Medicine and Dentistry 41 29%
Nursing and Health Professions 30 22%
Pharmacology, Toxicology and Pharmaceutical Science 7 5%
Agricultural and Biological Sciences 5 4%
Biochemistry, Genetics and Molecular Biology 5 4%
Other 22 16%
Unknown 29 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 34. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 April 2021.
All research outputs
#750,425
of 17,658,188 outputs
Outputs from Cochrane database of systematic reviews
#1,896
of 11,730 outputs
Outputs of similar age
#16,651
of 271,753 outputs
Outputs of similar age from Cochrane database of systematic reviews
#42
of 180 outputs
Altmetric has tracked 17,658,188 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,730 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 25.2. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 271,753 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 180 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.